Dabigatran is used for: Prophylaxis of postoperative venous thromboembolism; Atrial fibrillation.
Recorded in the NepalDoc medicine catalog for Dabigatran.
Dabigatran etexilate capsules are a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation, For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days, To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated…
From the U.S. FDA-approved label for Dabigatran. Full label: DailyMed.
Dabigatran etexilate capsules are a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation, For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days, To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated, For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery, For the treatment of venous thromboembolic events (VTE) in pediatric patients 8 to less than 18 years of age who have been treated with a parenteral anticoagulant for at least 5 days, To reduce the risk of recurrence of VTE in pediatric patients 8 to less than 18 years of age who have been previously treated 1.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients Dabigatran etexilate capsules are indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation.
From the U.S. FDA-approved label for Dabigatran. Full label: DailyMed.
Non-valvular Atrial Fibrillation in Adult Patients: o For patients with CrCl >30 mL/min: 150 mg orally, twice daily o For patients with CrCl 15 to 30 mL/min: 75 mg orally, twice daily, Treatment of DVT and PE in Adult Patients: o For patients with CrCl >30 mL/min: 150 mg orally, twice daily after 5 to 10 days of parenteral anticoagulation, Reduction in the Risk of Recurrence of DVT and PE in Adult Patients: o For patients with CrCl >30 mL/min: 150 mg orally, twice daily after previous treatment…
Directions from the U.S. FDA-approved label for Dabigatran — your doctor or pharmacist may advise differently.
Dabigatran etexilate capsules are contraindicated in patients with: Active pathological bleeding, History of a serious hypersensitivity reaction to dabigatran, dabigatran etexilate, or to one of the excipients of the product (e.g., anaphylactic reaction or anaphylactic shock), Mechanical prosthetic heart valve, Active pathological bleeding, History of serious hypersensitivity reaction to dabigatran etexilate capsules, Mechanical prosthetic heart valve
Excerpt from the U.S. FDA-approved label for Dabigatran. Talk to a pharmacist or doctor before use.
Bleeding: Dabigatran etexilate can cause serious and fatal bleeding Bioprosthetic heart valves: Dabigatran etexilate use not recommended Increased Risk of Thrombosis in Patients with Triple-Positive Antiphospholipid Syndrome: Dabigatran etexilate use not recommended 5.1 Increased Risk of Thrombotic Events after Premature Discontinuation Premature discontinuation of any oral anticoagulant, including dabigatran etexilate, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events.
Warnings and precautions excerpt from the U.S. FDA-approved label for Dabigatran — not a complete list. Talk to a pharmacist or doctor before use.
The following clinically significant adverse reactions are described elsewhere in the labeling: Increased Risk of Thrombotic Events after Premature Discontinuation Risk of Bleeding Spinal/Epidural Anesthesia or Puncture Thromboembolic and Bleeding Events in Patients with Prosthetic Heart Valves Increased Risk of Thrombosis in Patients with Triple-Positive Antiphospholipid Syndrome The most serious adverse reactions reported…
Excerpt from the U.S. FDA-approved label for Dabigatran — not a complete list. Talk to a pharmacist or doctor about side effects.
5 brands · 3 makers in the NepalDoc catalog — see the full Dabigatran guide →
Store at 20°C to 25°C (68°F to 77°F); Keep the bottle tightly closed. Store in the original package to protect from moisture.
Storage information from the U.S. FDA-approved label for Dabigatran.
What is Dabiclot?
Dabiclot 110mg Capsule is a Dabigatran medicine made by QbD Pharmaceuticals. It comes as 110mg Capsule.
What is Dabiclot used for?
Dabigatran is used for Prophylaxis of postoperative venous thromboembolism, Atrial fibrillation.
What is the generic name of Dabiclot?
The generic name of Dabiclot is Dabigatran.
Which brands of Dabigatran are available in Nepal?
5 brands of Dabigatran are listed in the NepalDoc catalog, from 3 makers — including Dabiclot 150mg Capsule, Dabirom 110MG Tablet, Pradaxa 110mg Capsule, Pradaxa 150mg Capsule.
What are the side effects of Dabigatran?
The following clinically significant adverse reactions are described elsewhere in the labeling: Increased Risk of Thrombotic Events after Premature Discontinuation Risk of Bleeding Spinal/Epidural Anesthesia or Puncture Thromboembolic and Bleeding Events in Patients with Prosthetic Heart Valves Increased Risk of Thrombosis in Patients with Triple-Positive Antiphospholipid Syndrome The most serious adverse reactions reported…
This page is information only and is not medical advice. Medicine details come from the sources listed above and may change — always confirm the medicine, strength and dose with a pharmacist or doctor before use. A catalog listing does not guarantee that a medicine is in stock at any pharmacy.
